He Jiang, Lai Tangmin, Zhou Zhiying, Yang Haonan, Lei Zheng, Zhou Liu, Li Nan, He Yu, Zeng Siwei, Munai Erha, Tan Yuanyuan, Wang Miaomiao, Zhang Yang, Zhou Wei, Wu Yongzhong
Radiation Oncology Center, Chongqing University Cancer Hospital, Chongqing, 400030, P. R. China.
College of Bioengineering, Chongqing University, Chongqing, 400044, P. R. China.
Sci Rep. 2025 Jul 9;15(1):24651. doi: 10.1038/s41598-025-09937-5.
The novel protein acylation modifications have played a vital role in protein post-translational modifications. However, the functions and effects of the protein acylation modifications in lung adenocarcinoma are still uncertain. Currently, there is still a lack of global identification of acylation modifications in lung adenocarcinoma cells. Therefore, in this study, we detected 10 currently known acylation modifications in lung adenocarcinoma cells by Western blot. We found that the abundance of lysine lactylation (Kla), crotonylation (Kcr) and succinylation (Ksu) is likely higher. Subsequently, we identified the above three modifications together with phosphorylation by global mass spectrometry-based proteomics in lung adenocarcinoma cells. As a result, we got 3110 Kla sites in 1220 lactylated proteins, 16,653 Kcr sites in 4137 crotonylated proteins, 4475 Ksu sites in 1221 succinylated proteins, and 15,254 phosphorylation sites in 4139 phosphorylated proteins. Recent studies have highlighted the role of lactylation modifications in tumor cell resistance to radiation and chemotherapy by affecting homologous recombination. Our subsequent investigations have shown that key factors in the nonhomologous end joining (NHEJ) pathway, such as Ku70 and Ku80, undergo lactylation modifications. Inhibition of lactylation impairs the efficiency of nonhomologous end joining. In conclusion, our results provide a proteome-wide database to study Kla, Kcr and Ksu and phosphorylation in lung adenocarcinoma, and new insights into the role of acylation modification in lung adenocarcinoma.
新型蛋白质酰化修饰在蛋白质翻译后修饰中发挥了至关重要的作用。然而,蛋白质酰化修饰在肺腺癌中的功能和作用仍不明确。目前,仍缺乏对肺腺癌细胞中酰化修饰的全面鉴定。因此,在本研究中,我们通过蛋白质免疫印迹法检测了肺腺癌细胞中目前已知的10种酰化修饰。我们发现赖氨酸乳酰化(Kla)、巴豆酰化(Kcr)和琥珀酰化(Ksu)的丰度可能较高。随后,我们通过基于质谱的蛋白质组学方法在肺腺癌细胞中对上述三种修饰以及磷酸化进行了全面鉴定。结果,我们在1220个乳酰化蛋白中获得了3110个Kla位点,在4137个巴豆酰化蛋白中获得了16653个Kcr位点,在1221个琥珀酰化蛋白中获得了4475个Ksu位点,在4139个磷酸化蛋白中获得了15254个磷酸化位点。最近的研究强调了乳酰化修饰通过影响同源重组在肿瘤细胞对放疗和化疗的抗性中的作用。我们随后的研究表明,非同源末端连接(NHEJ)途径中的关键因子,如Ku70和Ku80,会发生乳酰化修饰。抑制乳酰化会损害非同源末端连接的效率。总之,我们的结果提供了一个全蛋白质组数据库,用于研究肺腺癌中的Kla、Kcr和Ksu以及磷酸化,并为酰化修饰在肺腺癌中的作用提供了新的见解。